 OCALA, Fla., Oct. 06, 2021 GLOBE NEWSWIRE -- AIM ImmunoTech Inc. NYSE American: AIM today released detailed safety data from a Phase 1 clinical study which supports the companys belief that its drug Ampligen has significant potential as an intranasal therapeutic for COVID-19. 